<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893373</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-SORAML-034</org_study_id>
    <nct_id>NCT00893373</nct_id>
  </id_info>
  <brief_title>Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age</brief_title>
  <acronym>SORAML</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib is a multikinase inhibitor which is acting on various cellular pathways involved in
      the genesis of acute myeloid leukemia (AML). Sorafenib is therefore a promising candidate for
      improvement of chemotherapy results in AML. This clinical trial evaluates the efficacy of
      sorafenib added to standard chemotherapy for AML in patients between 18 and 60 years of age.
      Patients are randomised to receive either sorafenib capsules or placebo in addition to their
      chemotherapy. The placebo and the sorafenib group will be compared regarding event-free
      survival and other clinical outcomes. An event is either treatment failure or relapse or
      death. According to the study hypothesis, the sorafenib group will have less events than the
      placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remissions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Induction, Consolidation and Maintenance plus Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>Standard AML chemotherapy plus sorafenib 400 mg BID</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Standard AML chemotherapy plus placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with newly diagnosed AML (except APL) according to the FAB and WHO
             classification, including AML evolving from MDS or other hematologic diseases and AML
             after previous cytotoxic therapy or radiation (secondary AML)

          -  Bone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or
             differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of
             nonerythroid cells in the bone marrow must be leukemic blasts. In AML defined by
             cytogenetic aberrations, the proportion of blasts may be &lt; 20%.

          -  Age ≥ 18 and ≤ 60 years

          -  Informed consent, personally signed and dated to participate in the study

          -  ECOG performance status of 0-1

          -  Life expectancy of at least 12 weeks

          -  Adequate liver and renal function as assessed by laboratory requirements to be
             conducted within 7 days prior to Screening

        Exclusion criteria:

          -  Patients who are not eligible for standard chemotherapy as per discretion of the
             treating physician

          -  Central nervous system manifestation of AML

          -  Cardiac disease: heart failure NYHA III or IV; unstable coronary artery disease (MI
             more than 6 months prior to study entry is permitted); serious cardiac ventricular
             arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

          -  Chronically impaired renal function (creatinine clearance &lt; 30 ml/min)
             (Cockcroft-Gault formula)

          -  Patients undergoing renal dialysis

          -  Chronic pulmonary disease with relevant hypoxia

          -  Known HIV and/or hepatitis C infection

          -  Evidence or history of severe non-leukemia associated bleeding diathesis or
             coagulopathy

          -  Evidence or recent history of CNS disease, including primary or metastatic brain
             tumors, seizure disorders

          -  Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or
             diastolic 95 mmHg

          -  Any severe concomitant condition which makes it undesirable for the patient to
             participate in the study or which could jeopardize compliance of the protocol

          -  Patients with major surgery, open biopsy or significant traumatic injury within 4
             weeks of start of first dose

          -  Serious, non-healing wound, ulcer or bone fracture

          -  Uncontrolled active infection &gt; Grade 2 NCI-CTC version 3.0

          -  Concurrent malignancies other than AML

          -  History of organ allograft

          -  Allergy to study medication or excipients in study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Ehninger, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg Klinikum am Bruderwald</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Diakonie-Krankenhaus gGmbH Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakoniekrankenhaus Rotenburg</name>
      <address>
        <city>Rotenburg</city>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sal-aml.org</url>
    <description>SAL - Study Alliance Leukemia</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

